IRADIMED CORPORATION Reports Second Quarter 2026 Financial Results

IRADIMED CORPORATION Reports Second Quarter 2026 Financial Results

iRadimed Corporation Announces Regular Quarterly Cash Dividend of $0.20 Per Share Reaffirms Full-Year 2026 Revenue and Earnings Guidance Reports revenue of $20.5 million for the second quarter of 2026, which increased by $0.1 million, or 0.5% compared to the same period in 2025. Reports GAAP diluted EPS of $0.41 and non-GAAP diluted EPS of $0.46 for the second quarter of 2026. Declares a regular quarterly cash dividend of $0.20 per share of common stock for the second quarter of 2026, payable on August 28, 2026.

The Company is a leader in developing innovative magnetic resonance imaging (“MRI”) compatible medical devices and products. The Company is a provider of (i) non-magnetic intravenous (“IV”) infusion pump systems and (ii) a non-magnetic patient vital signs monitoring system that are each designed for use during MRI procedures.

“The second quarter marked the first step in the actual launch of the new 3870 MR IV pump and transitioning of IV pump revenue from the older 3860 to this next-generation 3870 platform. Second-quarter revenue was in line with our expectations, and the initial 3870 shipments met our plan. This was our first sizable production ramp of the new pump, with expected startup inertia and challenges, which were well managed by our manufacturing and engineering teams. We anticipate that as experience and volumes build through the balance of the year, we will continue to gain efficiencies, which we expect will be reflected in a higher gross margin in the second half of the year.

“We have been very pleased with our bookings for the quarter as domestic monitor unit bookings set a record, and the new 3870 bookings aligned with our expectations as we continue to get the 3870 in front of more customers. Of note, more than 70% of new pump orders were for our ‘quad stack’ configuration of four pumps on a single IV pole, an indication that customers are standardizing on this configuration for the 3870, and doubling the number of pump channels from the previous norm. We continue to expect the 3870 revenues to ramp significantly through the second half of the year,” said Roger Susi, President and Chief Executive Officer of Iradimed.

“For the third quarter of 2026, we expect revenue of $23.0 million to $24.5 million and GAAP diluted earnings per share of $0.49 to $0.54 and non-GAAP diluted earnings per share of $0.54 to $0.59. We reaffirm our guidance for the full-year 2026, expecting to report revenue of $91.0 million to $96.0 million, and GAAP diluted earnings per share of $1.90 to $2.05 and non-GAAP diluted earnings per share of $2.09 to $2.24,” added Mr. Susi.

The Company’s board of directors declared a regular quarterly cash dividend of $0.20 per share of our outstanding common stock. The dividend is payable to stockholders of record as of the close of business on August 14, 2026 and will be paid on August 28, 2026.

For the three months ended June 30, 2026, the Company reported revenue of $20.5 million, compared to $20.4 million for the comparable period of 2025, which increased by $0.1 million or 0.5%. The Company reported net income of $5.2 million, compared to $5.8 million for the comparable period of 2025, which decreased by 10%. Earnings per share decreased by $0.04 per diluted share or 9% to $0.41 per diluted share, for the three months ended June 30, 2026, compared to $0.45 per diluted share for the same period of 2025. For the three months ended June 30, 2026, the Company reported non-GAAP net income of $5.9 million, which excludes $0.6 million of stock compensation e...